ALIROCUMAB IN HIGH-RISK PATIENTS WITH BASELINE LDL-C ≥160 MG/DL: FINDINGS FROM THE COMPASSIONATE USE PROGRAM

被引：0
|
作者：
Glueck, Charles J.
Brown, Alan
Goldberg, Anne
McKenney, James
Kantaros, Louis
Stewart, John
Elassal, Joseph
Koren, Andrew
机构：
[1] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[2] Sanofi, Bridgewater, NJ USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2017年 / 69卷 / 11期
关键词：
D O I：
10.1016/S0735-1097(17)33544-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1203-309
引用
收藏
页码：155 / 155
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
    Henry N. Ginsberg
    Daniel J. Rader
    Frederick J. Raal
    John R. Guyton
    Marie T. Baccara-Dinet
    Christelle Lorenzato
    Robert Pordy
    Erik Stroes
    Cardiovascular Drugs and Therapy, 2016, 30 : 473 - 483
  • [2] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
    Ginsberg, Henry N.
    Rader, Daniel J.
    Raal, Frederick J.
    Guyton, John R.
    Baccara-Dinet, Marie T.
    Lorenzato, Christelle
    Pordy, Robert
    Stroes, Erik
    CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (05) : 473 - 483
  • [3] EFFICACY OF SWITCHING FROM STATIN MONOTHERAPY TO EZETIMIBE/SIMVASTATIN 10/20 mg VERSUS ROSUVASTATIN 10 mg IN HIGH-RISK PATIENTS ANALYZED BY BASELINE LDL-C
    Brudi, P.
    Averna, M.
    Farnier, M.
    Missault, L.
    Vaverkova, H.
    Viigimaa, L. M.
    Dong, Q.
    Shah, A.
    Taggart, W.
    Johnson-Levonas, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 189 - 189
  • [4] METABOLIC CAUSES OF HIGH-RISK LDL CHOLESTEROL (LDL-C)
    VEGA, GL
    GRUNDY, SM
    DENKE, MA
    ARTERIOSCLEROSIS, 1989, 9 (05): : A709 - A710
  • [5] Statin treated patients at very high cardiovascular risk: Are the majority close to LDL-C < 70 mg/dl?
    Gitt, A. K.
    Ambegaonkar, B.
    Brudi, P.
    Horack, M.
    Vanneste, B.
    Lautsch, D.
    EUROPEAN HEART JOURNAL, 2014, 35 : 679 - 679
  • [6] Alirocumab in high-risk patients: Observations from the open-label expanded use program
    Glueck, Charles J.
    Brown, Alan
    Goldberg, Anne C.
    McKenney, James M.
    Kantaros, Louis
    Stewart, John
    Elassal, Joseph
    Koren, Andrew
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 662 - 668
  • [7] FAVOURABLE IMPACT ON LIPID LEVELS OF INCREASING STATIN DOSE IN HIGH-RISK PATIENTS WITH VERY HIGH BASELINE LDL-C: RESULTS FROM VOYAGER
    Lundman, P.
    Palmer, M. K.
    Karlson, B. W.
    Barter, P. J.
    Nicholls, S. J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 164 - 164
  • [8] Should patients with high cardiovascular risk and an LDL-C concentration below 70 mg/dl be treated with aggressive statin therapy?
    Lee, Cheol Whan
    Park, Seung-Jung
    CLINICAL LIPIDOLOGY, 2012, 7 (01) : 1 - 4
  • [9] Under-treated high-risk patients: identifying patients in high-risk subgroups and treating them to LDL-C targets
    Schuster, H
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2005, 7 (0A) : A20 - A28
  • [10] The Heart Protection Study: High-risk patients benefit from statins, regardless of LDL-C level
    Gurm, HS
    Hoogwerf, B
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2003, 70 (11) : 991 - 997
12345